RESEARCH ARTICLE

Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections

Kuan-Meng Soo¹, Bahariah Khalid², Siew-Mooi Ching³,4, Hui-Yee Chee¹*

¹ Department of Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia, ² Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia, ³ Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia, ⁴ Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia

* cheehy@upm.edu.my

Abstract

Introduction

Dengue virus (DENV) infection is currently a major cause of morbidity and mortality in the world; it has become more common and virulent over the past half-century and has gained much attention. Thus, this review compared the percentage of severe cases of both primary and secondary infections caused by different serotypes of dengue virus.

Methods

Data related to the number of cases involving dengue fever (DF), dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS) or severe dengue infections caused by different serotypes of dengue virus were obtained by using the SCOPUS, the PUBMED and the OVID search engines with the keywords “(dengue * OR dengue virus *) AND (severe dengue * OR severity of illness index * OR severity * OR DF * OR DHF * OR DSS *) AND (serotypes * OR serogroup *)”, according to the MESH terms suggested by PUBMED and OVID.

Results

Approximately 31 studies encompassing 15,741 cases reporting on the dengue serotypes together with their severity were obtained, and meta-analysis was carried out to analyze the data. This study found that DENV-3 from the Southeast Asia (SEA) region displayed the greatest percentage of severe cases in primary infection (95% confidence interval (CI), 31.22–53.67, 9 studies, n = 598, I² = 71.53%), whereas DENV-2, DENV-3, and DENV-4 from the SEA region, as well as DENV-2 and DENV-3 from non-SEA regions, exhibited the greatest percentage of severe cases in secondary infection (95% CI, 11.64–80.89, 4–14 studies, n = 668–3,149, I² = 14.77–96.20%). Moreover, DENV-2 and DENV-4 from the SEA region had been found to be more highly associated with dengue shock syndrome (DSS).
(95% CI, 10.47–40.24, 5–8 studies, n = 642–2,530, $I^2 = 76.93–97.70\%$), while DENV-3 and DENV-4 from the SEA region were found to be more highly associated with dengue hemorrhagic fever (DHF) (95% CI, 31.86–54.58, 9 studies, n = 674–2,278, $I^2 = 55.74–88.47\%$), according to the 1997 WHO dengue classification. Finally, DENV-2 and DENV-4 from the SEA region were discovered to be more highly associated with secondary infection compared to other serotypes (95% CI, 72.01–96.32, 9–12 studies, n = 671–2,863, $I^2 = 25.01–96.75\%$).

**Conclusion**

This study provides evidence that the presence of certain serotypes, including primary infection with DENV-3 from the SEA region and secondary infection with DENV-2, DENV-3, and DENV-4 also from the SEA region, as well as DENV-2 and DENV-3 from non SEA regions, increased the risk of severe dengue infections. Thus, these serotypes are worthy of special consideration when making clinical predictions upon the severity of the infection.

**Systematic Review Registration**

PROSPERO CRD42015026093 (http://www.crd.york.ac.uk/PROSPERO)

**Introduction**

Dengue virus (DENV) infection has become more common and virulent over the past half-century. It is in fact, endemic in over 100 countries in Africa, America, and Asia, with 390 million new dengue fever infections [1] and approximately 12,000 deaths occurring worldwide every year [2].

The WHO classification on severe dengue infection changes over time. In the 1997 definition, dengue hemorrhagic fever was characterized by having plasma leakage, high fever, hemorrhagic phenomena, hepatomegaly and circulatory failure, whereas dengue shock syndrome was characterized by having narrow pulse pressure (<20 mmHg (2.7 kPa) [3]. Later in 2009, the classification was redefined, in which severe dengue infection was characterized by having plasma leakage, severe bleeding and severe organ impairment [4].

**1.1 Severity of different serotypes**

Dengue virus consists of four serotypes with $\geq 30\%$ difference in their overall amino acid sequences [5].

Patients can be infected with more than one serotype of dengue virus in their lifetime. Secondary infection with heterologous serotypes is more severe than primary infection, which may be explained by the antibody-dependent enhancement (ADE) theory. Based on this theory, primary infection leads to the formation of serotype-specific antibodies, which confer long-lasting immunity to the infecting serotype, but short-lasting immunity to other unexposed serotypes. Hence, for secondary infection with different serotypes, the antibodies produced are unable to neutralize the virus, but instead form immune complexes with the virus. These immune complexes have higher affinity towards Fcγ receptors on the surfaces of macrophages and other cells, and hence, enhance the entry of the virus into these cells, besides allowing viral replication to occur [6]. This theory was reported in a study that involved animal, in
which a higher peak viremia was found during secondary infection compared to that during primary infection [7].

In addition to the increased severity of secondary infection, certain serotypes were found to cause more severe infections than other serotypes, even during primary infection. For example, Anantapreecaa et al [8] reported that primary infection with DENV-1 caused severe infections (95% CI, 54.57–67.41) compared to other serotypes (95% CI, 4.58–52.96). This suggests that specific dengue serotypes also play a role in causing severe dengue infections. Moreover, when the immunogenic effects of different serotypes of dengue viruses were compared, it was found that the synthesized NS4A, NS4B, and E peptides of DENV-2 and DENV-3 induced higher total cytokine responses, which included TNF-α and IFN-γ, compared to other serotypes [9]. In contrast, DENV-4 was reported to be less immunogenic [10].

Furthermore, since many studies have shown that different serotypes caused different effects upon the severity of dengue infections, this meta-analysis gathered several published evidences from various regions, durations, as well as sample sizes of studies, and synthesized the combined data to evaluate the severity of dengue infection for different dengue serotypes.

Methods

2.1 Literature search

A systematic review of dengue hemorrhagic fever, dengue shock syndrome or severe dengue infection was undertaken based on the general principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements.

Data sources. A number of relevant articles had been identified via systematic search of MEDLINE from 1946 until present (via Ovid), Non-Indexed Citations (via Ovid), Embase from 1974 up to present (via Ovid), Scopus and PubMed. On top of that, in order to identify comprehensive studies that were not captured by the database searches, the reference lists of the published systematic reviews were manually screened and more articles were successfully retrieved after title and abstract exclusions.

Search strategies. A search of human studies in inception from February 11, 2014 until July 22, 2015 was performed by using subject headings and free text terms. A search was performed with the keywords “(dengue” OR dengue virus”) AND (severe dengue” OR severity of illness index” OR severity” OR DF” OR DHF” OR DSS”) AND (serotypes” OR serogroup”), according to the MESH terms suggested by PubMed and Ovid.

2.2 Inclusion criteria

Cross-sectional studies from all publication years concerning dengue patients from all age groups and regions were included. Articles published only in English were evaluated.

2.3 Exclusion criteria

The relevance of papers was determined by evaluating their types, objectives and methods. Reviews that did not contain original research data were excluded, so did proceedings that failed to employ the peer-review process. In addition, papers with objectives to study the effects of recombinant proteins from different dengue serotypes on respondents, as well as studies of patients colonized but not infected with dengue virus, were also excluded. Moreover, studies complicated with other diseases were excluded to ensure that dengue virus is the causative agent for all included cases. Finally, papers that did not separate primary infection cases from secondary infection cases were also excluded.
2.4 Data abstraction

**Study selection.** The titles and the abstracts of the literature search were screened by one reviewer for potentially relevant studies based on the eligibility criteria and they were further double-checked by a second reviewer. After excluding duplicate and apparently irrelevant studies, the full text of the remaining studies were read by two reviewers. The reasons for the exclusion of records were documented during full-text screening. Disagreements between the reviewers were resolved by consensus.

**Data extraction and quality assessment.** The following data were extracted independently and in duplicate by two reviewers into a data extraction form: the citation of the study; the number of participants; the characteristics of participants (study population, and age); the study duration; the serotyping method; the WHO classification method; as well as the number of cases that involved dengue hemorrhagic fever, dengue shock syndrome or severe dengue infection caused by different serotypes of the dengue virus. Disagreements were documented and resolved by discussion with a third reviewer; where doubt remained, the authors were contacted for clarification.

2.5 Data analysis

Meta-analysis was carried out by using Comprehensive Meta-Analysis (CMA) V3.3.070 software (USA). A fixed effect model and a random effect model were used to calculate the mean effect size in the selected studies without significant heterogeneity (p > 0.1) and with significant heterogeneity (p < 0.1), respectively. Besides, in order to identify factors that contributed to the heterogeneity, Begg’s funnel plot and Egger linear regression were employed to identify the presence of publication bias, with p < 0.05 considered as significant for the presence of publication bias. Additionally, sensitivity analysis or study omission analysis was carried out to locate a single study that was responsible for the heterogeneity.

2.6 Definition and Outcomes

Dengue serotypes were confirmed by using either an RT-PCR or an immunofluorescence assay serotyping method. Primary infection is a single infection, whereas secondary infection is an infection that occurs following a primary infection after some time interval. Both serotypes do not exist at the same time. On the other hand, concurrent infection with dual serotypes is defined as an infection with two serotypes of dengue virus that is present simultaneously in a patient. Meanwhile, severe dengue infection is defined as a severe infection, according to the WHO classification from 2009, or dengue hemorrhagic fever or dengue shock syndrome, according to the WHO classification from 1997. There were 2 outcomes that were studied in this meta-analysis. First, the effect size in percentage of severe dengue cases caused by each dengue serotype, subdivided to (1) primary and secondary infection, (2) SEA or non-SEA regions, and (3) 1997 and 2009 WHO dengue classification. Second, the effect size in percentage of secondary dengue infection caused by each dengue serotype subdivided to SEA and non-SEA regions.

**Results**

3.1 Results of literature search

The study selection process is depicted in Fig 1. The sample size, the study period, the population, the age, and the method of serotyping are presented in Table 1. All the selected studies had been retrospective cross-sectional studies. Thirty-one studies were included for review, with 1 study containing data from both Southeast and non-Southeast Asia regions. Moreover,
thirty studies portrayed only the severe DHF caused by different dengue serotypes, which was not specific to the severe DHF caused by primary or secondary infection with dengue serotypes. Out of the 30 authors of the papers contacted, 1 of them, Alonso D [11], responded to provide unpublished data.

3.2 The relationship between dengue serotypes and disease severity

The effect size of the percentage of severe dengue infections is shown in Fig 2. No meta-analysis was performed for primary DENV-1, secondary DENV-1 and secondary DENV-4 infections in non-SEA regions as it required more than one study. DENV-4 displayed the lowest total number of cases in both SEA and non-SEA regions (8.08% and 1.07%) compared to other serotypes. Hence, sensitivity analysis was carried out by omitting each individual study to observe its impact upon the quality and the consistency of the results. The results suggested that the study conducted by Nisalak et al [20] was reported to affect the heterogeneity of primary DENV-3 infection in the SEA region, while studies carried out by Guzman et al and Ocazionez et al [42,43] were reported to affect the heterogeneity of secondary DENV-3 infection in non-SEA regions. The heterogeneity did not remain significant after the studies were excluded. The remaining study groups contained no single study that significantly affected the effect size and quality.

Furthermore, the analysis (Fig 2) showed that secondary infection caused a greater percentage of severe infections than primary infection. When the data from all dengue serotypes were clustered into primary, secondary, and concurrent infections and were compared, concurrent infection was found to have higher percentage of severe cases than secondary infection, followed by primary infection. For primary infection, DENV-3 from the SEA region resulted in the highest percentage of severe infections, whereas DENV-2 and DENV-3 from non-SEA regions, as well as DENV-2, DENV-3 and DENV-4 from the SEA region, resulted in greater percentages of severe infections for secondary infection.
When the severity of dengue infections from the SEA region was compared with that of non-SEA regions (Peru, Cuba, France, Colombia, and Brazil), except secondary infections by DENV-2 and DENV-3; all primary and secondary dengue infections had lower percentage of severe cases in non-SEA regions than in the SEA region.

Moreover, DENV-2 and DENV-4 from the SEA region (95% CI, 14.21–14.54), as well as DENV-2 and DENV-3 from non-SEA regions (95% CI, 32.32–35.89), showed a greater difference in the percentage of severe dengue infections between primary and secondary infections compared to other serotypes.

### Table 1. Demographic profile.

| Study | Total number of cases included in this meta-analysis | Population | Sample collection year | Age (years) | Serotyping | WHO classification method (year) |
|-------|----------------------------------------------------|------------|------------------------|-------------|------------|----------------------------------|
| [13]  | 150 Indonesia                                       | 1975–1978  | 0–14                   |             | Hemagglutination-inhibition (HI) test | NA |
| [14]  | 106 Indonesia                                       | 1995–1996  | 4–9                    |             | RT-PCR, PRNT | 1997 |
| [15]  | 8                                                 | 1975–1978  | NA                     | <14         | IF, RT-PCR | NA |
| [16]  | 165 Thailand                                       | NA         | 1–78                   |             | RT-PCR | 1997 |
| [17]  | 87                                                 | 1998–2000  | <12                    |             | RT-PCR | 1986 |
| [18]  | 29                                                 | 1998–2000  | 3–14                   |             | ELISA | 1997 |
| [19]  | 257 Thailand                                       | 1973–1999  | 18                      |             | NA | 1999 |
| [20]  | 5616 Thailand                                      | 1998–2000  | 12                     |             | RT-PCR | 1997 |
| [21]  | 104 Thailand                                       | 1999–2002  | All ages               |             | IF | NA |
| [22]  | 99                                                 | 2002       | All ages               |             | RT-PCR | 1997 |
| [23]  | 28                                                 | 2004       | 1–72                   |             | RT-PCR | 1997 |
| [24]  | 20                                                 | 2007–2008  | 1.5–7 months           |             | RT-PCR | 1997 |
| [25]  | 22                                                 | 2007–2009  | 3 months               |             | RT-PCR | 1997 |
| [26]  | 167 Vietnam                                        | 2006–2008  | 5–15                   |             | RT-PCR | 2009 |
| [27]  | 76                                                 | 2008       | 18–31                  |             | Real time RT-PCR | 1997 |
| [28]  | 209 Vietnam                                        | 2007–2008  | 17–27                  |             | Real time RT-PCR | 1997 |
| [41]a | 99 Cambodia, Vietnam, French, Brazil               | 2006–2007  | All ages               |             | RT-PCR | 2009 |
| [29]  | 394 Thailand                                       | 2006–2009  | <14                    |             | RT-PCR | 1997 |
| [30]  | 133 Thailand                                       | 2006–2008  | 3–14                   |             | RT-PCR | 1997 |
| [31]  | 64                                                 | 2005–2006  | 7–22                   |             | RT-PCR | 1997 |
| [32]  | 134 Thailand                                       | 1994–2002  | All ages               |             | RT-PCR | 1997, 2009 |
| [33]  | 451 Singapore                                      | 2005–2011  | 18–87                  |             | RT-PCR | 1997, 2009 |
| [34]  | 40                                                 | 2000–2001  | NA                     |             | RT-PCR | 1997 |
| [42]  | 3926 Chile, Cuba                                   | 1981, 1997 | All ages               |             | PRNT | NA |
| [35]  | 4                                                 | 2001–2002  | NA                     |             | RT-PCR, PRNT | 1994 PAHO |
| [43]  | 89                                                 | 1998–2004  | NA                     |             | IF | 1980 |
| [36]  | 21                                                 | 1998–2004  | NA                     | >15         | RT-PCR | 1997 |
| [37]  | 225 Mexico                                         | 2009       | NA                     |             | RT-PCR | 1997 |
| [11]b | 45                                                 | 2011       | All ages               |             | RT-PCR | 2009 |
| [38]  | 258 Brazil                                         | 2011       | 17–64                  |             | RT-PCR | 2012 |

*a* represents paper that contains respondents from both Southeast Asia and non-Southeast Asia (Latin America (Brazil, France)) regions

*b* represents unpublished data

*c* represents Pan American Health Organization

NA represents not available

doi:10.1371/journal.pone.0154760.t001
In addition, the effect size of the percentages of DHF, DSS and severe dengue infections is shown in Fig 3. According to 1997 WHO classification, DENV-3 and DENV-4 were found to result in higher percentage of DHF, whereas DENV-2 and DENV-4 had higher percentage of DSS, compared to other serotypes. According to 2009 WHO classification, DENV-2 from non-SEA regions were found to result in higher percentage of severe dengue infections than other serotypes.

### 3.3 The relationship between dengue serotypes and secondary infection

The effect size of the percentage of secondary infection is shown in Fig 4. DENV-2 and DENV-4 from the SEA region were found to result in higher percentages for secondary infection than other serotypes (95% CI, 72.01–96.32, 9–12 studies, n = 671–2863, $I^2 = 25.01–96.75\%$). Moreover, the percentage of secondary infection in the SEA region had been found to be higher than that of non-SEA regions. Moreover, results derived from the sensitivity analysis suggested that a study conducted by Dussart et al [41] was reported to affect the heterogeneity of DENV-2 infections in SEA regions and DENV-3 infections in non-SEA regions, while a study carried out by Libraty et al [24] was reported to affect the heterogeneity of DENV-3 infections in the SEA region. The heterogeneity did not remain significant after these studies were excluded. The remaining study groups contained no single study that significantly affected the effect size and quality.

### 3.4 Results of publication bias assessment

When analyzing all 29 studies that examined the association between dengue serotypes and severity, publication bias was detected by using Egger’s test ($p = 0.000 (<0.05)$), but not

---

### Table: effect size of the relationship between dengue serotypes and percentage of severe cases

| Dengue serotypes | Primary/ secondary infections | SEA/ Non SEA | Total number of studies | Total number of cases | Heterogeneity, $I^2$ | Rate and 95% CI | 95%, CI |
|------------------|-----------------------------|-------------|------------------------|----------------------|---------------------|----------------|---------|
| DENV4            | Secondary                   | SEA         | 9                      | 668                  | 88.53               | 52.86          | 35.22–69.82 |
| DENV2            | Secondary                   | SEA         | 14                     | 2490                 | 96.20               | 50.72          | 34.84–66.45 |
| DENV2            | Secondary                   | Non-SEA     | 4                      | 3149                 | 14.77               | 49.61          | 47.86–51.36 |
| DENV3            | Secondary                   | SEA         | 13                     | 1670                 | 94.27               | 46.04          | 30.84–62.01 |
| DENV3            | Secondary                   | Non-SEA     | 4                      | 848                  | 81.68               | 42.75          | 11.64–80.89 |
| DENV3            | Primary                     | SEA         | 9                      | 598                  | 71.53               | 42.03          | 31.22–53.67 |
| DENV4            | Primary                     | SEA         | 2                      | 26                   | 75.62               | 38.65          | 8.90–80.24  |
| DENV2            | Primary                     | SEA         | 6                      | 114                  | 30.80               | 36.18          | 27.57–45.77 |
| DENV1            | Secondary                   | SEA         | 13                     | 2050                 | 95.32               | 35.08          | 22.95–49.50 |
| DENV1            | Primary                     | SEA         | 7                      | 674                  | 86.74               | 32.60          | 20.86–47.02 |
| DENV2            | Primary                     | Non-SEA     | 2                      | 99                   | 86.50               | 13.72          | 9.98–71.81  |
| DENV3            | Primary                     | Non-SEA     | 2                      | 68                   | 0.00                | 10.43          | 5.05–20.32  |
| DENV4            | Primary                     | Non-SEA     | 2                      | 45                   | 0.00                | 4.78           | 1.20–17.24  |
| All              | Concurrent                  | SEA         | 2                      | 18                   | 79.08               | 53.80          | 9.26–93.00  |
| All              | Secondary                   | Non-SEA     | 7                      | 4019                 | 55.36               | 48.29          | 35.84–60.95 |
| All              | Secondary                   | SEA         | 14                     | 6878                 | 98.54               | 41.52          | 28.44–55.91 |
| All              | Primary                     | SEA         | 11                     | 1412                 | 85.44               | 36.66          | 27.65–46.72 |
| All              | Primary                     | Non-SEA     | 5                      | 330                  | 90.27               | 10.57          | 2.66–33.81  |

Fig 2. Pooled effect size of the relationship between dengue serotypes and percentage of severe cases. The data are arranged in a descending order based on the percentage of severe cases of dengue serotypes. The data are separated by primary and secondary infections, as well as SEA and non-SEA regions, regardless of the WHO classification.

doi:10.1371/journal.pone.0154760.g002
Fig 3. Pooled effect size of the relationship between dengue serotypes and percentage of DHF, DSS, as well as severe dengue infections. The data are arranged in a descending order based on the percentages of DHF, DSS and severe dengue infections. The data are separated by 1997 and 2009 WHO dengue classifications.

Fig 4. Pooled effect size of the relationship between dengue serotypes and secondary infection. The data are separated by SEA and non-SEA regions.

### 1997 WHO dengue classification

| Dengue serotypes | SEA/ Non SEA | Total number of studies | Total number of cases | Heterogeneity, $I^2$ | Rate and 95% CI | Effect size (percentage of DHF) | 95%, CI lower limit | Upper limit |
|------------------|--------------|-------------------------|----------------------|----------------------|----------------|---------------------------------|---------------------|-------------|
| DENV4            | SEA          | 9                       | 674                  | 55.74                |                | 43.91                           | 33.78               | 54.58       |
| DENV3            | SEA          | 9                       | 2278                 | 88.47                |                | 41.28                           | 31.86               | 51.4        |
| DENV2            | SEA          | 9                       | 2534                 | 89.01                |                | 35.30                           | 26.99               | 44.6        |
| DENV1            | SEA          | 9                       | 3557                 | 96.87                |                | 30.72                           | 20.5                | 43.25       |

### 2009 WHO dengue classification

- ■ represents Non-SEA
- ◆ represents SEA

Fig 3. Pooled effect size of the relationship between dengue serotypes and percentage of DHF, DSS, as well as severe dengue infections. The data are arranged in a descending order based on the percentages of DHF, DSS and severe dengue infections. The data are separated by 1997 and 2009 WHO dengue classifications.

Fig 4. Pooled effect size of the relationship between dengue serotypes and secondary infection. The data are separated by SEA and non-SEA regions.

doi:10.1371/journal.pone.0154760.g003
doi:10.1371/journal.pone.0154760.g004
detected by using Begg’s test \( p = 0.8219 \text{ (>0.05)} \). Besides, for all 18 studies that examined the association of secondary infection, publication bias was detected by using Egger’s test \( p = 0.007 \text{ (<0.05)} \), but not detected by using Begg’s test \( p = 0.211 \text{ (> 0.05)} \) (Fig 5).

**Discussion**

Previous meta-analyses have addressed the epitope characteristics \[39\] and the host metabolism of dengue virus \[40\]: the association between clinical signs \[44\] or temperature change \[45\] and the risk of dengue infection: as well as current treatments for dengue infection such as the tetravalent vaccine \[46\], steroids \[47\] and supportive treatments such as fluid bolus \[48\] or vector control measures \[49,50\]. Nonetheless, this meta-analysis compared the percentage of severe cases of different serotypes of dengue virus in primary and secondary infections. Data from previous studies were collected and combined to achieve a sufficient sample size from both primary and secondary infections by each dengue serotype.

4.1 The association between dengue serotypes and severity

Secondary infection by each serotype showed greater percentage of severe cases than the respective primary infection (Fig 2). This strengthens the evidence that antibody-dependent enhancement occurs during secondary infection, which causes more severe infections. Meanwhile, concurrent infection with dual serotypes is defined as a simultaneous infection with two serotypes of the dengue virus. The results showed that concurrent infections had greater percentage of severe cases than secondary infections and primary infections (Fig 2), although the difference was small (about 5%). Moreover, Guzman et al and Anderson et al \[42,51\] discovered that the longer the interval between the primary and secondary infections, the greater the risk of DHF. Hence, this finding suggests that concurrent infection with multiple serotypes, which represents zero time interval between primary and secondary infections, may present greater severity than both primary and secondary infections. However, as this study only managed to obtain two concurrent infections reported with the percentage of severe cases from SEA regions, the sample size needs to be increased in the future before any conclusion can be made.
According to the 1997 WHO classification, percentage of severe cases of two serotypes were found to be 8–10% higher than other serotypes, whereas according to the 2009 WHO classification, percentage of severe cases of one serotype (DENV-2 from non-SEA regions) was found to be 30% higher than other serotypes. This suggests that 2009 WHO dengue classification showed clearer difference in association of dengue serotypes to the percentage of severe cases. Besides, it was further reported that the 2009 WHO dengue classification is better at representing levels of disease severity [52]. This finding also suggests that the use of different dengue classifications affects the clinical prediction of severity caused by each serotype.

4.2 The association between dengue serotypes and secondary infections

The SEA region depicted a higher percentage of secondary dengue infection than non-SEA regions (Fig. 4), particularly DENV-2 and DENV-4 infections. This finding may be due to the presence of different genotypes in these regions. In particular, the DENV-2 American and Asian/American genotypes have been commonly reported in non-SEA regions [53–55], while the DENV-2 Asian I, II, cosmopolitan and American Asian genotypes have been commonly reported in the SEA region [53,56–58]. The DENV-2 American genotype is less virulent during secondary infection [59], and may cause patients to not present clinically, therefore lowering the number of secondary cases recorded. Moreover, the DENV-2 Asian genotype was found to be more associated with secondary infection compared to the DENV-2 American/Asian genotype [56].

Nevertheless, studies performed in 2002–2008 in the European Network for Diagnosis of Imported Viral Diseases (ENIVD) showed that the presence of the dengue virus 2 Asian I, II and cosmopolitan genotypes, as well as all dengue virus 4 genotypes (I, II, III, IV and cosmopolitan) among travelers from SEA to Europe. Besides, spreading of the Asian genotypes has been reported in a few other studies in countries in South America (Colombia, Brazil, and Venezuela) [34,43].

In addition, a higher percentage of secondary infection may also be due to the higher prevalence of dengue outbreaks in the SEA region than non-SEA regions (South America and Europe), which has caused many patients to have a history of past infections. Although there was no significant difference between the number of dengue cases per person and the regions (95% CI SEA-0.1; non-SEA-0.3) from 2002–2015, based on the data obtained from previous studies ([60–70], data shown S1 Supporting Information sheet 4 Supporting Information sheet 4), many more dengue cases remained unreported. Moreover, the SEA region displayed a higher percentage of secondary infection, although the majority of studies included in SEA reflected belong to infants, who were less likely to have a history of past infections (Table 1). This suggests that dengue cases may be more prevalent in the SEA region, as the populations have been proven to experience dengue infection at a young age.

Meanwhile, DENV-4 portrayed the lowest percentage of the sample size among all four serotypes in both SEA and non-SEA regions (8.08% and 1.07%, according to Fig. 2). Genotypes I and II of DENV-4 showed negative correlations with each other, suggesting an internal competition between the genotypes [71]. Moreover, another study reported that DENV-4 is transmitted through the Aedes albopictus mosquito, a different species from other serotypes (Aedes aegypti) that dwells in areas away from the urban areas with lower human population, and hence, causes a lower rate of transmission [72,73]. The reasons underlying the reduced circulation of DENV-4, in fact, require further investigation.

4.3 Limitations

Throughout the study, only a small portion of data from non-SEA regions (Cuba, Peru, France, Colombia and Brazil) had been obtained. Many studies were excluded because they did not
separate the primary from the secondary cases of dengue infections caused by each dengue serotype. Some studies were excluded because there were no DHF or severe dengue cases recorded. Therefore, this data was removed to avoid problems in computation of the effect size as suggested by Sterne and Bradburn [74]. Hence, although the results (Fig 2) showed that secondary infection by DENV-2 and DENV-3 from non-SEA regions had higher percentage of severe cases than those in the SEA region, this does not imply that dengue infections in non-SEA regions are more severe. Torres and Castro [75] showed that only 3.4% of the sample size of 427,627 dengue patients in Latin America suffered from DHF, which is lower than the percentages shown in this study (10.57% and 48.29% in primary and secondary infections of all dengue serotypes, respectively). Use of different WHO classification was also found to affect the association between dengue serotypes and severe cases. More studies are needed in the future before any conclusions can be made. Moreover, publication bias was identified in this study, which suggests that more unpublished data are needed for more robust statistical results. On top of that, sensitivity analysis was performed, and studies that affected the consistency and the quality of the results were identified as they affected the robustness of the statistical results.

Besides, as studies included are retrospective studies, they present with inferior level of evidence compared to prospective studies. Details such as days of admission and age of patients in each dengue serotypes and in primary and secondary infections were only recorded in 6 and 12 studies, respectively, out of 31 studies included in this meta-analysis (data shown in S1 Supporting Information document sheet 6). Hence, no meta-regression was performed. Aging was found to be associated with co-morbidities that lead to impairments of kidney, liver and lung [76–78], that comprise the 2009 WHO classification definition of severe cases. Late admission of dengue cases and inadequate monitoring in hospital may also enhance severity of infections. These details are crucial as they may become confounding factors for the study of association between dengue serotypes, types of infections and percentage of severe dengue cases. Future studies that consider these confounding factors are needed.

4.4 Conclusion

As the severity of dengue infection had been found to be affected by the dengue serotypes involved and also the interval between the primary and secondary infections, these factors need to be considered when clinical prediction of the severity of dengue patients is being made. Moreover, as certain serotypes resulted in higher percentage of severe cases, such as secondary infection by SEA DENV-2, DENV-3, DENV-4, and non-SEA DENV-2, DENV-3 or primary infections by DENV-3 from SEA: these serotypes require proper clinical attention.

Moreover, since DENV-4 was found to cause the lowest percentage of the sample size; serotype-specific antiviral treatments may be more focused on the other serotypes, DENV-1, DENV-2 and DENV-3. Besides, as DENV-2 and DENV-4 had been more associated with secondary infection, patients with a history of past dengue infection should take extra precautions during outbreaks of DENV-2 and DENV-4 infections.

Supporting Information

S1 Prisma Checklist. Prisma 2009 checklist. (DOCX)

S1 Supporting Information. Sheet 1 Relationship between dengue serotypes and percentage of severe cases Sheet 2 Relationship between dengue serotypes and percentage of DHF, DSS, as well as severe dengue infections Sheet 3 Relationship between dengue serotypes and secondary infection Sheet 4 Dengue cases in SEA and non-SEA regions Sheet 5 Publication bias Sheet 6
Age and days of admissions of patients
(XLSX)

Acknowledgments
We would like to thank all authors for their helpful replies throughout the process of finding unpublished data. We also would like to take this opportunity to thank Mr. Diego Allonso for providing unpublished data used in this manuscript and Prof. Lye Munn Sann for all helpful comments. Our gratitude is also extended to the Ministry of Higher Education, Malaysia for funding KMS in his Ph.D. study. Besides, we would like to acknowledge the Ministry of Higher Education, Malaysia for granting us the Long-term Research Grant Scheme (LRGS) LR001/2011A in supporting this review in terms of technical issues like payment of proof reading. Nonetheless, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions
Analyzed the data: KMS. Wrote the paper: KMS. Read, provided feedback and approved the final manuscript: BK SMC HYC.

References
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL. The global distribution and burden of dengue. Nature. 2013; 496(7446):504–7. doi: 10.1038/nature12060 PMID: 23563266
2. Bouzid M, Colón-González FJ, Lung T, Lake IR, Hunter PR. Climate change and the emergence of vector-borne diseases in Europe: case study of dengue fever. BMC Public Health. 2014; 14:781. doi: 10.1186/1471-2458-14-781 PMID: 25149418
3. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edition. Geneva: World Health Organization. World Health Organization. 1997.
4. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. World Health Organization; 2009.
5. Lisova O, Belkadi L, Bedouelle H. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus. J Mol Recognit. 2014; 27(4):205–214. doi: 10.1002/jmr.2352 PMID: 24591178
6. Gallin J, Fauci A. Emerging Infections. Academic Press; 1998. Available: https://books.google.com/books?hl=en&lr=&id=ycjk63shxtAC&pgis=1.
7. MOLL ML, Takasaki T, Omatsu T, Nakamura S, Katakai Y, Ami Y, et al. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans. J Gen Virol. 2014; 95(3):591–600. doi: 10.1099/vir.0.060384-0 PMID: 24323638
8. Anantapreecha S, Chanama S, A-Nuegoonpipat A, Naemkhunthot S, Sa-Ngasang A, Sawanpanyalert P, et al. Serological and virological features of dengue fever and dengue haemorrhagic fever in Thailand from 1999 to 2002. Epidemiol Infect. 2005; 133(3):503–507. PMID: 15962557
9. Bashyam HS, Green S, Rothman AL. Dengue Virus-Reactive CD8+ T Cells Display Quantitative and Qualitative Differences in Their Response to Variant Epitopes of Heterologous Viral Serotypes. J Immunol. 2006; 176(5):2817–2824. PMID: 16493038
10. Suzarte E, Marcos E, Gil L, Valdes I, Lazo L, Ramos Y, et al. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol. 2014; 159(7):1629–1640. doi: 10.1007/s00705-013-1956-4 PMID: 24420159
11. Allonso D, Meneses MDF, Fernandes CA, Ferreira DF, Mohana-Borges R. Assessing positivity and circulating levels of NS1 in samples from a 2012 dengue outbreak in Rio de Janeiro, Brazil. Moreira LA, ed. PLoS One. 2014; 9(11):e113634. doi: 10.1371/journal.pone.0113634 PMID: 25412084
12. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazquez S, et al. Epidemiologic studies on dengue in santiago de cuba, 1997. Am J Epidemiol. 2000; 152(8):793–799. PMID: 11053589
13. Gubler DJ, Suharyono W, Tan R, Abidin M, Sie A. Viraemia in patients with naturally acquired dengue infection. Bull World Health Organ. 1981; 59(4):623–630. PMID: 6976230

14. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, Ma’roef C, et al. A prospective seroepidemiologic study on dengue in children four to nine years of age in yogyakarta, Indonesia I. studies in 1995–1996. Am J Trop Med Hyg. 1999; 61(5):412–419. PMID: 10497982

15. Loroño-Pino MA, Crop CB, Farfán JA, Vorndam AV, Rodríguez-Angulo EM, Rosado-Paredes EP, et al. Common occurrence of concurrent infections by multiple dengue serotypes. Am J Trop Med Hyg. 1999; 61(5):725–730. PMID: 10586902

16. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. J Infect Dis. 2000; 181(1):2–9. PMID: 10608744

17. Conwin a L, Larasati RP, Bangs MJ, Wuryadi S, Arjos o S, Sukri N, et al. Epidemic dengue transmission in southern Sumatra, Indonesia. Trans R Soc Trop Med Hyg. 2001; 95(3):257–265. PMID: 11490992

18. Endy TP, Nisalak A, Chunsuttiwat S, Green S, Rothman AL, et al. Spatial and temporal circulation of dengue virus serotypes: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol. 2002; 156(1):52–59. PMID: 12076888

19. Stephens HAF, Klaythong R, Sirikong M, Vaughn DW, Green S, Kalayanarooj S, et al. HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens. 2002; 60(4):309–318. PMID: 12472660

20. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, Scott RM, et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg. 2003; 68(2):191–202. PMID: 12641411

21. Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004; 189(6):990–1000. PMID: 14999601

22. Limkittrikul K, Yingsakmongkon S,jitmittraphap A. Clinical differences among PCR-proven dengue serotype infections. Southeast Asian J Trop Med Public Heal. 2005; 36(6):1–7.

23. Suwandono A, Kosasih H, Nurhayati, Kusriastuti R, Harun S, Ma’roef C, et al. Four dengue virus serotypes found circulating during an outbreak of dengue fever and dengue haemorrhagic fever in Jakarta, Indonesia, during 2004. Trans R Soc Trop Med Hyg. 2006; 100(9):855–862. PMID: 16507313

24. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009; 6(10):e1000171. doi: 10.1371/journal.pmed.1000171 PMID: 19859541

25. Capeding RZ, Brion JD, Caponpon MM, Gibbons RV, Jarman RG, Yoon IK, et al. The Incidence, Characteristics, and Presentation of Dengue Virus Infections during Infancy. Am J Trop Med Hyg. 2010; 82(2):330–336. doi: 10.4269/ajtmh.2010.09-0542 PMID: 20134013

26. Duyen HTL, Ngoc T V., Ha DT, Hang VTT, Kieu NTT, Young PR, et al. Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: Differential effects according to serotype and immune status. J Infect Dis. 2011; 203(9):1292–1300. doi: 10.1093/infdis/jir104 PMID: 21335662

27. Fox A, Le NMH, Simonsen CP, Wolbers M, Wertheim HFL, Khuong PT, et al. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis. 2011; 5(3):e967. doi: 10.1371/journal.pntd.0000967 PMID: 21390156

28. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. Harris E, ed. PLoS Negl Trop Dis. 2011; 5(9):e1309. doi: 10.1371/journal.pntd.0001309 PMID: 21909448

29. Sabchareon A, Sirivichayakul C, Limkittrikul K, Chanthavanchi P, Suvannabadda S, Jiwiaryavej V, et al. Dengue Infection in Children in Ratchaburi, Thailand: A Cohort Study. I. Epidemiology of Symptomatic Acute Dengue Infection in Children, 2006–2009. Halstead SB, ed. PLoS Negl Trop Dis. 2012; 6(7):e1732. doi: 10.1371/journal.pntd.0001732 PMID: 22860141

30. Sirivichayakul C, Limkittrikul K, Chanthavanchi P, Jiwiaryavej V, Chokejindachai W, Pengsaa K, et al. Dengue infection in children in ratchaburi, thailand: A cohort study. ii. clinical manifestations. PLoS Negl Trop Dis. 2012; 6(2).

31. Velasco JMS, Alera MTP, Ypil-Cardenas CA, Dimaan EM, Jarman RG, Chinnawirotpisan P. Demographic, clinical and laboratory findings among adult and pediatric patients hospitalized with dengue in the Philippines. Southeast Asian J Trop Med Public Health. 2014; 45(2):337–45. PMID: 24968673

32. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, Yoon IK, Kalayanarooj S, Thipayamongkolgul M, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010. BMC Public Health. 2015; 15(1):1–10.
33. Yung CF, Lee KS, Thein TL, Tan LK, Gan VC, Wong JGX, et al. Dengue Serotype-Specific Differences in Clinical Manifestation, Laboratory Parameters and Risk of Severe Disease in Adults, Singapore. Am J Trop Med Hyg. 2015.

34. Montoya Y, Holechek S, Caceres O, Burans J, Guevara C, et al. Circulation of Dengue Viruses in North-Western Peru, 2001; 27:2000–2001.

35. Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, Gonzalez D, et al. Dengue hemorrhagic fever caused by sequential dengue 1–3 virus infections over a long time interval: Havana epidemic, 2001–2002. Am J Trop Med Hyg. 2006; 75(6):1113–1117. PMID: 17172378

36. De Carvalho Bittencourt M, Martial J, Cabié A, Thomas L, Césaire R. Decreased Peripheral Dendritic Cell Numbers in Dengue Virus Infection. J Clin Immunol. 2011; 32(1):161–172. doi: 10.1007/s10875-011-9592-9 PMID: 21969208

37. De la Cruz-Hernandez SI, Flores-Aguilar H, Gonzalez-Mateos S, Lopez-Martinez I, Alpuche-Aranda C, Ludert JE, et al. Determination of Viremia and Concentration of Circulating Nonstructural Protein 1 in Patients Infected with Dengue Virus in Mexico. Am J Trop Med Hyg. 2013; 88(3):446–454. doi: 10.4269/ajtmh.12-0023 PMID: 23339203

38. Martins VDCA, Bastos M de S, Ramasawamy R, de Figueiredo RP, Gimaque JBL, Braga WSM, et al. Clinical and virological descriptive study in the 2011 outbreak of dengue in the Amazonas, Brazil. PLoS One. 2014; 9(6):e100535. doi: 10.1371/journal.pone.0100535 PMID: 24978469

39. Vaughan K, Greenbaum J, Blythe M, Peters B, Sette A. Meta-analysis of All Immune Epitope Data in the Flavivirus Genus: Inventory of Current Immune Epitope Data Status in the Context of Virus Immunity and Immunopathology. Viral Immunol. 2010; 23(3):259–284. doi: 10.1089/vim.2010.0006 PMID: 20565291

40. Maynard ND, Gutschow M V, Birch EW, Covert MW. The virus as metabolic engineer. Biotechnol J. 2010; 5(7):686–694. doi: 10.1002/biot.201000080 PMID: 20665642

41. Dussart P, Baril L, Petit L, Beniguel L, Quang LC, Ly S, et al. Clinical and Virological Study of Dengue Cases and the Members of Their Households: The Multinational DENFRAME Project. Harris E, ed. PLoS Negl Trop Dis. 2012; 6(1):e1482. doi: 10.1371/journal.pntd.0001482 PMID: 22292098

42. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica. 2002; 11(4):223–227. PMID: 12049030

43. Ocazionez RE, Cortés FM, Villar LA, Gómez SY. Temporal distribution of dengue virus serotypes in Colombian endemic area and dengue incidence. Re-introduction of dengue-3 associated to mild febrile illness and primary infection. 2006; 101(November):725–731.

44. Zhang H, Zhou YP, Peng HJ, Zhang XH, Liu ZH, et al. Predictive Symptoms and Signs of Severe Dengue Disease for Patients with Dengue Fever: A Meta-Analysis. Biomed Res Int. 2014; 2014:1–10.

45. Fan J, Wei W, Bai Z, Fan C, Li S, Liu Q, et al. A systematic review and meta-analysis of dengue risk with temperature change. Int J Environ Res Public Health. 2015; 12(1):1–15.

46. Da Costa VG, Marques-Silva AC, Florianov GA, Moreli ML. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. Vaccine. 2014; 32 (39):4885–4892. doi: 10.1016/j.vaccine.2014.07.008 PMID: 25045816

47. Menon K, McNally D, Choong K, Sampson M. A systematic review and meta-analysis on the effect of steroids in pediatric shock. Pediatr Crit Care Med. 2013; 14(5):474–80. doi: 10.1097/PCC.0b013e31828a8125 PMID: 23867428

48. Ford N, Hargreaves S, Shanks L. Mortality after Fluid Bolus in Children with Shock Due to Sepsis or Severe Infection: A Systematic Review and Meta-Analysis. von Seidlein L, ed. PLoS One. 2012; 7(8):e43953. doi: 10.1371/journal.pone.0043953 PMID: 22952819

49. Al-Muhandis N, Hunter PR. The value of educational messages embedded in a community-based approach to combat dengue Fever: a systematic review and meta regression analysis. PLoS Negl Trop Dis. 2011; 5(8):e1278. doi: 10.1371/journal.pntd.0001278 PMID: 21886848

50. Erfanger T, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological parameters in developing countries: a systematic review and meta-analysis. Med Vet Entomology. 2008; 22:203–221.

51. Anderson KB, Gibbons RV, Cummings DAT, Nisalak A, Green S, Libraty DH, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical Illness in a school-based cohort in Thailand. J Infect Dis. 2014; 209(3):360–368. doi: 10.1093/infdis/jit436 PMID: 23964110

52. Horstick O, Ranzinger S. Reporting progress on the use of the WHO 2009 dengue case classification: a review. Southeast Asian J Trop Med Public Heal. 2015; 46(1):49–54.
53. Twiddy SS, Farrar JJ, Chau NV, Wills B, Gould E, Gritsun T, et al. Phylogenetic Relationships and Differential Selection Pressures among Genotypes of Dengue-2 Virus. 1. 2002; 72:63–72.

54. Salazar MI, Loroñol-Pino MA, Farfán-Ale JA, Olsen KE, Beaty BJ. American and American/Asian genotypes of dengue virus differ in mosquito infection efficiency: candidate molecular determinants of productive vector infection. Rev Biolomédica. 2010; 21(3):121–135.

55. Drumond BP, Mondini A, Schmidt DJ, de Bronzoni RVM, Bosch I, Nogueira ML. Circulation of Different Lineages of Dengue Virus 2, Genotype American/Asian in Brazil: Molecular and Phylogenetic Characterization. PLoS One. 2013; 8(3).

56. Hang VTT, Holmes EC, Veasna D, Quy NT, Hien TT, Quail M, et al. Emergence of the Asian 1 genotype of dengue Virus serotype 2 in viet Nam: in vivo fitness advantage and lineage replacement in Southeast Asia. PLoS Negl Trop Dis. 2010;4(7).

57. Salda LTD, Parquet MDC, Matias RR, Natividad FF, Kobayashi N, Morita K. Molecular epidemiology of dengue 2 viruses in the Philippines: Genotype shift and local evolution. Am J Trop Med Hyg. 2005; 73(4):796–802. PMID:16222028

58. Caballero-anthony M, Cook ADB, Gayle G, Amul H, Sharma A. Health Governance and Dengue in Southeast Asia. 2015;(2:).

59. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet. 1999; 354:1431–1434. PMID:10543670

60. World bank. World Development Indicators—Google Public Data Explorer. Available at: https://www.google.com/publicdata/explore?ds=d5bncppjof8f9_&met_y=sp_pop_totl&idim=country:COM:DJI:CPV&hl=en&dl=en.

61. Worldometer. Population of Brazil (2015)—Worldometers. Available at: http://www.worldometers.info/world-population/brazil-population/.

62. Break dengue. Asia Pacific | Break Dengue. Available at: http://www.breakdengue.org/in-your-area/asia-pacific/.

63. WHO, WHO | Dengue and severe dengue. 2015. Available at: http://www.who.int/mediacentre/factsheets/fs117/en/.

64. Lei-Win T. Dengue fever cases hit a high in parts of Southeast Asia -media. 2013. Available at: http://www.trust.org/item/20130625114148-6jwhn/.

65. Hunt L. Dengue Fever on the Rise in Southeast Asia. 2014. Available at: http://thediplomat.com/2014/02/dengue-fever-on-the-rise-in-southeast-asia/.

66. Chaichalearmmongkol N. Dengue Fever Sweeps Southeast Asia—WSJ. Wall Str J. 2013. Available at: http://www.wsj.com/articles/SB100014241278873235855604579008510278710696.

67. Cunha J. Dengue Fever Symptoms, Causes, Treatment—What geographic areas are at high risk for contracting dengue fever?—MedicineNet. 2015. Available at: http://www.medicinenet.com/dengue_fever/page2.htm.

68. Nguyen C. Dengue Escalates in Southeast Asia | HealthMap. Outbreak News. 2015. Available at: http://www.healthmap.org/site/diseasedaily/article/dengue-escalates-southeast-asia-62015.

69. Dengue Virus Net. Dengue Epidemiology and Countries at Risk of Dengue Transmisison. 2015. Available at: http://www.denguevirusnet.com/epidemiology.html.

70. Government of Canada PHA of C. Dengue Fever: Global Update—Travel Health Notice—Public Health Agency of Canada. 2012. Available at: http://www.phac-aspc.gc.ca/trp-pmv/notices-avis/notices-avis-eng.php?id=44.

71. Villabona-Arenas CJ, Zanotto PMDA. Evolutionary history of Dengue virus type 4: insights into genotype phyldynamics. Infect Genet Evol. 2011; 11(5):878–85. doi: 10.1016/j.meegid.2011.02.007 PMID: 21335103

72. Abubaker S, Shafee N. Outlook of Dengue in Malaysia: a Century Later. Malaysian J Pathol. 2002; 24(1):23–27.

73. Fang R, Lo E, Lim TW. The 1982 dengue epidemic in Malaysia: epidemiological, serological and virological aspects. Southeast Asian J Trop Med Public Health. 1984; 15(1):51–8. PMID: 6740379

74. Sterne JAC, Bradburn MJ. Meta-analysis in Stata. Syst Rev Heal Care. 2001:347–369.

75. Torres JR, Castro J. The health and economic impact of dengue in Latin America. Cad Saude Publica. 2007; 23:23–31.

76. Kang DH, Anderson DH, Kim YG, Mazzalli M, Suga S, Jefferson JA. Impaired Angiogenesis in the Aging Kidney: Vascular Endothelial Growth Factor and Thrombospondin-1 in Renal Disease. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2001; 37(3):601–11.
77. Marchesini G, Bua V, Brunori A, Bianchi G, Pisi P, Fabbri A. Galactose Elimination Capacity and Liver Volume in Aging Man. Hepatology. 1988; 8(5):1079–83. PMID: 3417228

78. Santana H, Zoico E, Turcato E, Tosoni P, Bissoli L, Olivieri M. Relation between Body Composition, Fat Distribution, and Lung Function in Elderly Men. Am J Clin Nutr. 2001; 73(4):827–31. PMID: 11273860